Navigation Links
Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference
Date:1/24/2008

Conference will be held Feb. 11-13 at the Waldorf-Astoria Hotel in New York

City

NEW YORK, Jan. 24 /PRNewswire/ -- Gerson Lehrman Group (GLG) and the Biotechnology Industry Organization (BIO) today announced a collaborative agreement designed to strengthen the access to clinical information and insights at the tenth annual BIO CEO & Investor Conference.

"We're thrilled to have this unique partnership opportunity with BIO in their tireless efforts to increase the relevant and timely dissemination of some of the most highly technical and challenging scientific issues of today," said Alexander Saint-Amand, Chief Executive Officer of GLG. "Our company's long-standing mission is to empower decision-makers by connecting them to the academic and industry leaders driving innovation and productivity in our global economy."

Through this partnership, BIO will tap into GLG's network of experts from around the world in order to identify the most relevant thought leaders to discuss the latest issues and trends affecting drug development and clinical design in the biotechnology industry.

"Gerson Lehrman Group is an ideal partner for BIO's annual investment conferences with deep access to the clinical experts and investigators who can bring insights to pipeline research and current clinical practices," said James C. Greenwood, president and CEO of BIO. "Our Therapeutic Workshops and Business Roundtable discussions focus on educating investors and industry management on the issues that face product innovation, capitalization and commercialization."

The BIO CEO & Investor Conference is the largest independent biotechnology investor conference focused on publicly-traded companies. The conference features issue-oriented plenary sessions, educational sessions on therapeutic areas and business issues, company presentations, one-on-one meetings, and networking opportunities.

To see the latest updates on 2008 programming and speakers for BIO CEO & Investor Conference, please visit http://ceo.bio.org/opencms/ceo/2008/index.jsp.

About Gerson Lehrman Group

Gerson Lehrman Group (GLG) provides technology and services to support a marketplace for expertise. Since 1998, its platform for consultation and collaboration has helped the world's leading financial services firms, consultancies, corporations, and nonprofits find, engage, and manage experts in a broad range of industries and disciplines. GLG's unparalleled network of the world's leading expert consultants, known as the GLG Councils, includes more than 175,000 subject-matter experts who educate and provide insight to decision-makers through a wide range of consulting methods, including telephone consultations, expert surveys and seminars. GLG has invested in one of the world's most sophisticated infrastructures for expert recruiting and compliance. For more information about GLG, please visit http://www.glgroup.com.

About BIO and the Tenth Annual BIO CEO & Investor Conference

Now in its tenth year, the BIO CEO & Investor Conference is the largest independent biotechnology investor conference focused on publicly-traded companies. The conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities. The conference is hosted by the Biotechnology Industry Organization (BIO), representing more than 1,150 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO produces the BIO International Convention, the world's largest gathering of the biotechnology industry.

Contacts:

Gerson Lehrman Group

Margaret M. Molloy

212 880-6569

mmolloy@glgroup.com


'/>"/>
SOURCE Gerson Lehrman Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group
2. Kiwa Bio-Tech Products Group Holds Meetings to Build Distribution Network
3. Animal Protection Groups Condemn FDAs Endorsement of Animal Cloning
4. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
5. The Jordan Company, L.P. Has Teamed with the Management of Haas TCM Inc. to Form Haas TCM Group Inc.
6. Maxygen to Present at the Stanford Group Company 13th Annual Healthcare Conference
7. Bioscience Group Warns Policymakers Against Complacency
8. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
9. Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei
10. The Ensign Group, Inc. Declares Quarterly Dividend of $0.04 Per Share
11. AG Mednet to Provide Image Network for Southwest Oncology Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research ... Inc. has been selected for membership in ARCS Alumni Hall of Fame ...
(Date:10/11/2017)... ... ... eye wash is a basic first aid supply for any work environment, but most personal ... rinse first if a dangerous substance enters both eyes? It’s one less decision, and likely ... dual eye piece. , “Whether its dirt and debris, or an acid or alkali, getting ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
Breaking Biology Technology:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):